Ubidecarenone

Summary

Ubidecarenone (CHEMBL454801) is an approved small-molecule ferroptosis inhibitor (ATC C01EB09); indicated across 38 conditions including cardiovascular disorder and preeclampsia.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: C01EB09
• Indications: 38 conditions
• Clinical trials: 109
• Chemistry: 863.3 Da · C59H90O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL454801
Name	Ubidecarenone
Type	Small molecule
Max phase	3
FDA approved	yes
PubChem CID	5281915
ChEBI	CHEBI:46245
ATC	C01EB09
Molecular formula	C59H90O4
Molecular weight	863.3
InChIKey	ACTIUHUUMQJHFO-UPTCCGCDSA-N

SMILES: CC1=C(C(=O)C(=C(C1=O)OC)OC)C/C=C(\C)/CC/C=C(\C)/CC/C=C(\C)/CC/C=C(\C)/CC/C=C(\C)/CC/C=C(\C)/CC/C=C(\C)/CC/C=C(\C)/CC/C=C(\C)/CCC=C(C)C

IUPAC name: 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyltetraconta-2,6,10,14,18,22,26,30,34,38-decaenyl]-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione

ChEBI definition: A ubiquinone having a side chain of 10 isoprenoid units. In the naturally occurring isomer, all isoprenyl double bonds are in the E- configuration.

Pharmacological roles (ChEBI): antioxidant, ferroptosis inhibitor.

Other ChEBI roles (chemical / environmental): human metabolite.

Also known as: Adelir, API 31510, API-31510, Aqua q10, Bio-quinone q10, Bpm-31510, Bpm31510, Co-enzyme q10, Coenzyme q-10, Coenzyme q-199, Coenzyme q10, Coq10

Patent coverage: 15,532 distinct patent families (38,240 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Prelamin-A/C.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
LMNA	7.95	Potency	11.2	nM	CHEMBL_ACT_3648358

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

38 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
cardiovascular disorder	3	MONDO:0004995	EFO:0000319
preeclampsia	3	MONDO:0005081	EFO:0000668
myalgic encephalomeyelitis/chronic fatigue syndrome	3	MONDO:0005404	EFO:0004540
multiple organ dysfunction syndrome	3	MONDO:0043726	EFO:1001373
chronic kidney disease	3	MONDO:0005300	EFO:0003884
Parkinson disease	3	MONDO:0005180	MONDO:0005180
Huntington disease	3	MONDO:0007739	MONDO:0007739
Duchenne muscular dystrophy	3	MONDO:0010679	MONDO:0010679
inborn mitochondrial metabolism disorder	3	MONDO:0004069	MONDO:0044970
metabolic dysfunction-associated steatohepatitis	3	MONDO:0007027	EFO:1001249
hepatocellular carcinoma	2	MONDO:0007256	EFO:0000182
heart failure	2	MONDO:0005252	EFO:0003144
squamous cell carcinoma	2	MONDO:0005096	EFO:0000707
cardiac arrest	2	MONDO:0000745	EFO:0009492
diastolic heart failure	2	MONDO:0006727	EFO:1000899
glioblastoma	2	MONDO:0018177	EFO:0000519
coronary artery disorder	2	MONDO:0005010	EFO:0001645
depressive disorder	2	MONDO:0002050	MONDO:0002050
polycystic ovary syndrome	2	MONDO:0008487	EFO:0000660
exocrine pancreatic carcinoma	2	MONDO:0005192	EFO:0002618
amyotrophic lateral sclerosis	2	MONDO:0004976	MONDO:0004976
type 1 diabetes mellitus	2	MONDO:0005147	MONDO:0005147
Prader-Willi syndrome	2	MONDO:0008300	MONDO:0008300
progressive supranuclear palsy	2	MONDO:0019037	MONDO:0019037
juvenile idiopathic arthritis	2	MONDO:0011429	EFO:0002609
bipolar disorder	2	MONDO:0004985	MONDO:0004985
gliosarcoma	1	MONDO:0016681	EFO:1001465
basal cell carcinoma	1	MONDO:0020804	EFO:0004193
cerebellar ataxia	1	MONDO:0000437	MONDO:0000437
breast neoplasm	1	MONDO:0021100	MONDO:0007254
epidermolysis bullosa	1	MONDO:0006541	EFO:1000690
lichen planus, oral	1	MONDO:0043923	EFO:0008517
Charcot-Marie-Tooth disease	1	MONDO:0015626	MONDO:0015626
injury	0	MONDO:0021178	EFO:0000546
Crohn disease	0	MONDO:0005011	EFO:0000384

3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 109.

Phase distribution

Phase	Trials
Not specified	41
PHASE2	23
PHASE2/PHASE3	12
PHASE3	10
PHASE4	8
PHASE1	7
EARLY_PHASE1	5
PHASE1/PHASE2	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05942027	PHASE4	RECRUITING	Role of Coenzyme Q10 in Chronic Kidney Disease
NCT06619249	PHASE4	RECRUITING	Effect of Endurance Training-Induced Coenzyme Q10 (CoQ10) Supplementation on Myokine, Exerkine Secretion and Cognitive Functions in Long-Distance Runners
NCT06743802	PHASE4	RECRUITING	The Effect of Coenzyme Q10 in Preventing Pain After Thoracoscopic Surgery
NCT00590408	PHASE4	TERMINATED	Efficacy and Safety of Coenzyme Q10 in the Treatment of Statin-Associated Myalgia
NCT02115581	PHASE4	COMPLETED	Coenzyme Q10 Supplementation in Children With Idiopathic Dilated Cardiomyopathy
NCT03104998	PHASE4	WITHDRAWN	Neotililty Trial: Effect of Coenzyme Q10 on Semen Parameters in Men With Idiopathic Infertility
NCT04302532	PHASE4	COMPLETED	Coenzyme q 10 and Fertility Outcome in Women With Clomiphene Resistant PCOS
NCT05711810	PHASE4	COMPLETED	Medicine-induced Cardiac Hemodialysis on COVID-19
NCT05422534	PHASE3	RECRUITING	CoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease
NCT06405204	PHASE3	NOT_YET_RECRUITING	of Myo-inositol, Melatonin and Co-enzyme q10 on Ovarian Reserve
NCT07234422	PHASE3	RECRUITING	The SELEQT-HF (SELEnium and CoQ10 NuTrition for Heart Failure) Study Will Evaluate the Effect of Adding Selenium/and coQ10 on Top of Standard HF Therapy in Patients With HF and Will do so Using a Pragmatic, Registry Based Randomized Controlled Trial in the Netherlands.
NCT00300937	PHASE3	COMPLETED	Coenzyme Q10 Supplementation and Development of Preeclampsia
NCT00308113	PHASE3	TERMINATED	CoQ10 and Prednisone in Non-Ambulatory DMD
NCT00532571	PHASE2/PHASE3	COMPLETED	Effects of Coenzyme Q10 in PSP and CBD
NCT00608881	PHASE3	TERMINATED	Coenzyme Q10 in Huntington’s Disease (HD)
NCT00860847	PHASE3	COMPLETED	Firefighter Aged Garlic Extract Investigation With CoQ10 as a Treatment for Heart Disease (FAITH)
NCT01032993	PHASE2/PHASE3	COMPLETED	Clinical Trial of CoQ10 for Mild-to-Moderate Statin-Associated Muscle Symptoms
NCT01126697	PHASE2/PHASE3	COMPLETED	Clinical Trial of Coenzyme Q10 and Lisinopril in Muscular Dystrophies
NCT01163500	PHASE2/PHASE3	COMPLETED	Coenzyme Q10 in Relation of the Lipid Peroxidation, Antioxidant Enzyme Activities in Coronary Artery Disease Patients
NCT01424761	PHASE2/PHASE3	COMPLETED	Coenzyme Q10 in Relation to the Antioxidative Vitamins, Oxidative Stress and Inflammation in Coronary Artery Disease Patients During Statin Therapy
NCT01892176	PHASE2/PHASE3	COMPLETED	Effects of High-dose Coenzyme Q10 on Biomarkers of Oxidative Damage and Clinical Outcome in Parkinson Disease
NCT01940627	PHASE2/PHASE3	COMPLETED	Influence of a Short Term Supplementation With Ubiquinol on Diverse Aspects Related to the Physical Activity
NCT01964001	PHASE2/PHASE3	COMPLETED	The Effects of Vitamin B-6 and Coenzyme Q10 Status on Oxidative Stress, Antioxidant Capacities, and Inflammatory Responses in Patients With Liver Cancer
NCT02333305	PHASE3	COMPLETED	Evolution of Albumin on AOA1 Patients Supplemented With Coenzyme Q10
NCT02622672	PHASE2/PHASE3	COMPLETED	Water-soluble Ubiquinol Supplementation on Blood Glucose, Lipids, Oxidative Stress, and Inflammation in Diabetes
NCT02865460	PHASE3	COMPLETED	Coenzyme Q10 Phase III Trial in Gulf War Illness
NCT03968640	PHASE3	WITHDRAWN	Efficacy of Coenzyme Q10 Supplementation on Multi-Organ Dysfunction in Severely Burned Patients
NCT05293132	PHASE2/PHASE3	COMPLETED	Effect of Montelukast Versus Co Enzyme in Sepsis
NCT05871086	PHASE2/PHASE3	UNKNOWN	Coenzyme Q10 in Juvenile Idiopathic Arthritis Patients
NCT06640465	PHASE2/PHASE3	COMPLETED	Comparing the Effects of Commercially Available Dietary Supplements on CoQ10 Concentrations
NCT04752813	PHASE2	ACTIVE_NOT_RECRUITING	A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)
NCT05873673	PHASE2	ACTIVE_NOT_RECRUITING	Coenzyme Q10 and Dentoalveolar Cyst
NCT00004731	PHASE2	COMPLETED	Parkinson’s Disease Treatment With Coenzyme Q10
NCT00033189	PHASE2	COMPLETED	An Open-label Pilot Study of Coenzyme Q10 in Steroid-Treated Duchenne Muscular Dystrophy
NCT00076492	PHASE2	COMPLETED	NINDS Parkinson’s Disease Neuroprotection Trial of CoQ10 and GPI 1485
NCT00243932	PHASE2	COMPLETED	Clinical Trial of High Dose CoQ10 in ALS
NCT00327756	PHASE2	WITHDRAWN	Mitochondrial Dysfunction in the Pathophysiology and Treatment of Bipolar Disorder
NCT00328874	PHASE2	COMPLETED	Study About Safety and Efficacy of Coenzyme Q10 in Progressive Supranuclear Palsy
NCT00541164	PHASE1/PHASE2	COMPLETED	Effects of Coenzyme Q10 on Charcot-Marie-Tooth Disease
NCT00652080	PHASE1/PHASE2	COMPLETED	An Open-Label Safety Study of API 31510 in a Topical Cream for in Situ Cutaneous Squamous Cell Carcinoma (SCCIS)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).